Store | Donate | Print Page | Contact Us | Report Abuse | Sign In | Join COVD
Share |

CITT-ART Study Needs Participants

The National Eye Institute of the National Institutes of Health recently announced that they funded a 5-year, 8 million dollar study called the Convergence Insufficiency Treatment Trial - Attention and Reading Study (CITT-ART).  This randomized, placebo controlled, clinical trial is a national multi-centered, collaborative research project designed to study the effectiveness of vision therapy for improving reading and attention after the treatment of convergence insufficiency in children 9 to <14 years of age.  The National Study Chair is Mitchell Scheiman, OD, Dean of Research at Salus University. Lynn Mitchell, MAS, an Associate Professor at The Ohio State University, College of Optometry is the Principal Investigator of the Data Coordinating Center and participating clinical study centers include:

Clinical Study Center


Bascom Palmer

Susanna Tamkins, OD

Children’s Hospital of Akron

Richard Hertle, MD

Ohio State University, College of Optometry,

Marjean Kulp, OD

NOVA – College of Optometry

Stacey Coulter, OD

Pennsylvania College of Optometry at Salus University

Michael Gallaway, OD

Southern California College of Optometry at Ketchum University

Susan Cotter, OD

State University of New York, College of Optometry

Jeffrey Cooper, OD

University of Alabama, Birmingham College of Optometry

Wendy Marsh Tootle, OD

CITT ART Reading Center

Christopher Chase, PhD

These researchers will be recruiting eligible patients between the ages of 9 to <14 years old to participate in this study.  The objectives of the CITT are: 1) to compare the effectiveness of  office-based vision therapy and office-based placebo vision therapy for the treatment of symptomatic convergence insufficiency, 2) to develop more precise estimates of the success rates of convergence insufficiency treatment; and 3) to identify factors that may be associated with successful treatment of convergence insufficiency. 

Approximately 324 patients will be entered into the study and cared for by participating study centers.  The study will last 2 years, with office visits once per week for 3 months for the OBVT and SVT groups, and once per month for the PPT group.  There will also be a 6-month follow-up visit for all subjects.  The results of this clinical trial should provide quality data and new information about the effectiveness of vision therapy for improving reading and attention.  

The CITT group will begin recruiting patients in August 2014.  This is your opportunity to contribute to our shared goal of improving the quality of the vision therapy research.  If you examine any patient between the ages of 9 to <14 years with symptomatic convergence insufficiency, please consider referring the patient to participate in this important study. Recruitment for clinical trials is always very challenging and your help is vital to make this study a success.  

For further information or to refer a patient please contact: 

Mitchell Scheiman, OD
CITT-ART Study Chair
Dean of Research, Salus University
8360 Old York Rd
Elkins Park, PA 19027
Phone: 215-276-1427
Fax: 888-206-5081